FULCRUM THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.28 USD | +1.78% |
|
-1.57% | -6.96% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 375.4 | 319.5 | 717 | 378.9 | 417.3 | 383.5 | - | - |
| Enterprise Value (EV) 1 | 278.7 | 206.6 | 498.8 | 176 | 181.1 | 146.5 | 254.2 | 383.5 |
| P/E ratio | -2.05 x | -4.2 x | -7.72 x | -2.98 x | -4.25 x | -4.8 x | -3.88 x | -5.07 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 36.2 x | 37.4 x | 59.7 x | 149 x | 8.85 x | 20.1 x | 4.5 x |
| EV / Revenue | - | 23.4 x | 26 x | 27.8 x | 64.6 x | 3.38 x | 13.3 x | 4.5 x |
| EV / EBITDA | -3.39 x | -2.98 x | -6.35 x | -1.6 x | -1.67 x | -1.42 x | -2.36 x | -4.68 x |
| EV / FCF | - | -3.76 x | -6.22 x | -1.78 x | -1.98 x | -1.37 x | -2.37 x | -3.48 x |
| FCF Yield | - | -26.6% | -16.1% | -56.3% | -50.5% | -73.1% | -42.1% | -28.7% |
| Price to Book | 4.33 x | 3.45 x | 3.4 x | 1.91 x | - | - | - | - |
| Nbr of stocks (in thousands) | 22,558 | 27,281 | 40,529 | 52,051 | 61,823 | 62,154 | - | - |
| Reference price 2 | 16.64 | 11.71 | 17.69 | 7.280 | 6.750 | 6.170 | 6.170 | 6.170 |
| Announcement Date | 20-03-05 | 21-03-04 | 22-03-03 | 23-03-09 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 8.823 | 19.16 | 6.342 | 2.805 | 43.32 | 19.08 | 85.13 |
| EBITDA 1 | -82.16 | -69.23 | -78.54 | -109.7 | -108.5 | -103.5 | -107.9 | -82.03 |
| EBIT 1 | -84.22 | -71.61 | -81.05 | -112.1 | -110.7 | -98.1 | -113.9 | -90.83 |
| Operating Margin | - | -811.64% | -422.97% | -1,768.12% | -3,945.24% | -226.44% | -597.16% | -106.7% |
| Earnings before Tax (EBT) 1 | -82.68 | -70.82 | -80.85 | -109.9 | -97.34 | -81.95 | -110.4 | -92.56 |
| Net income 1 | -82.68 | -70.82 | -80.85 | -109.9 | -97.34 | -82.28 | -106.4 | -92.78 |
| Net margin | - | -802.66% | -421.89% | -1,732.43% | -3,470.05% | -189.92% | -557.46% | -109% |
| EPS 2 | -8.130 | -2.790 | -2.290 | -2.440 | -1.590 | -1.286 | -1.589 | -1.218 |
| Free Cash Flow 1 | - | -55 | -80.19 | -99.01 | -91.47 | -107.1 | -107.1 | -110.1 |
| FCF margin | - | -623.34% | -418.47% | -1,561.23% | -3,261.07% | -247.11% | -561.13% | -129.31% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-05 | 21-03-04 | 22-03-03 | 23-03-09 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.058 | 2.592 | 1.882 | 1.183 | 0.685 | 0.295 | 0.88 | 0.759 | 0.871 | - | 41.11 | 0.1178 | 7.154 | - | - |
| EBITDA | -22.94 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.56 | -26 | -34.24 | -23.89 | -28.01 | -27.94 | -27.29 | -27.44 | -27.99 | -29.83 | 0.158 | -30.3 | -23.56 | -37.23 | -41.4 |
| Operating Margin | -465.78% | -1,003.01% | -1,819.08% | -2,019.44% | -4,089.2% | -9,471.19% | -3,101.36% | -3,615.28% | -3,213.78% | - | 0.38% | -25,732.14% | -329.29% | - | - |
| Earnings before Tax (EBT) 1 | -23.48 | -25.93 | -34.07 | -23.74 | -26.14 | -24.78 | -23.78 | -24.02 | -24.76 | -26.87 | 4.952 | -29.62 | -30.64 | -39.85 | -39.25 |
| Net income 1 | -23.48 | -25.93 | -34.07 | -23.74 | -26.14 | -24.78 | -23.78 | -24.02 | -24.76 | -26.87 | 1.202 | -27.67 | -27.99 | -39.85 | -39.25 |
| Net margin | -464.29% | -1,000.31% | -1,810.31% | -2,006.59% | -3,815.33% | -8,399.66% | -2,702.61% | -3,164.3% | -2,842.25% | - | 2.92% | -23,494.74% | -391.28% | - | - |
| EPS 2 | -0.5800 | -0.6400 | -0.8300 | -0.5100 | -0.5000 | -0.4100 | -0.3800 | -0.3900 | -0.4000 | -0.4300 | -0.0125 | -0.4488 | -0.4525 | -0.6400 | -0.6300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-03-03 | 22-05-09 | 22-08-11 | 22-11-08 | 23-03-09 | 23-05-15 | 23-08-03 | 23-11-07 | 24-02-27 | 24-05-13 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 96.7 | 113 | 218 | 203 | 236 | 237 | 129 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -55 | -80.2 | -99 | -91.5 | -107 | -107 | -110 |
| ROE (net income / shareholders' equity) | -94.9% | -77.7% | -52.7% | -53.5% | -44.8% | -37.5% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 3.850 | 3.390 | 5.210 | 3.820 | - | - | - | - |
| Cash Flow per Share 2 | -3.570 | -2.120 | -2.220 | -2.160 | -1.480 | -1.000 | -0.8300 | - |
| Capex 1 | - | 1.34 | 1.71 | 1.96 | 0.51 | 1.18 | 1.11 | 1.42 |
| Capex / Sales | - | 15.21% | 8.94% | 30.95% | 18.11% | 2.72% | 5.82% | 1.67% |
| Announcement Date | 20-03-05 | 21-03-04 | 22-03-03 | 23-03-09 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.28
USD
Average target price
15.78
USD
Spread / Average Target
+151.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.96% | 383M | |
| +21.85% | 46.93B | |
| +37.63% | 39.08B | |
| -8.05% | 38.48B | |
| +29.04% | 31.01B | |
| -13.75% | 26.14B | |
| +10.65% | 25.88B | |
| +38.43% | 12.53B | |
| -6.92% | 11.36B | |
| -12.29% | 10.65B |
- Stock Market
- Equities
- FULC Stock
- Financials Fulcrum Therapeutics, Inc.
